Safety and efficacy of thrombolysis in patients with underlying markers of CAA: insights from AcT скачать в хорошем качестве

Safety and efficacy of thrombolysis in patients with underlying markers of CAA: insights from AcT

Aravind Ganesh, MD, University of Calgary, Calgary, Canada, comments on the safety and efficacy of thrombolysis in patients with underlying markers of cerebral amyloid angiopathy (CAA), sharing insights from the AcT trial (NCT03889249). Dr Ganesh notes that patients with a high burden of chronic superficial siderosis may be at increased risk of hemorrhage after thrombolysis, whereas those with white matter disease features of CAA are not, and emphasizes that the results do not determine whether these patients can benefit from thrombolysis. This interview took place at the 2026 International Stroke Congress (ISC), held in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.